Trump’s Plan for Medicare Drug Talks Offers Pharma Fresh Fight (opens in new tab)

The Trump administration’s proposal for the fourth cycle of the Biden-initiated Medicare drug price negotiations includes provisions that have drawn skepticism from pharmaceutical giants, opening a new path for legal challenges.